Browse medicines
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Showing 1–60 of 319 records
Insulin glargine (Lantus)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Once-daily background insulin for type 1 and type 2 diabetes
Etanercept (Enbrel)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Rheumatoid arthritis, psoriasis and related long-term inflammatory diseases
Insulin Aspart (NovoLog / Fiasp / NovoLog Mix 70/30 / Kirsty / Merilog / Garzulys)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Diabetes — the fast insulin taken around meals
Epoetin alfa (Epogen / Procrit)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Low red blood cell count caused by kidney failure, HIV treatment or chemotherapy
Alteplase (Activase / Cathflo Activase)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Emergency clot-dissolving treatment for stroke, heart attack and major pulmonary embolism
Insulin Degludec (Tresiba)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Diabetes — the once-daily background insulin that lasts over 42 hours
Peginterferon Alfa-2a (Pegasys)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Long-standing hepatitis B or hepatitis C, treated by stimulating the immune system rather than by attacking the virus directly
Insulin Detemir (Levemir)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Diabetes — the background insulin that works through the day
Insulin lispro (Humalog)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Fast-acting mealtime insulin for type 1 and type 2 diabetes
Somatropin (Humatrope)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Children who are not growing normally, and adults with a damaged pituitary gland
Aflibercept (Eylea)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Leaking abnormal blood vessels at the back of the eye, in macular degeneration and in diabetes
Fibrinogen Concentrate (Human) (Riastap / Fibryga)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Replacing the protein that clots are actually made of, in people born without enough of it
Filgrastim (Neupogen)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Rebuilding infection-fighting white cells knocked down by chemotherapy
Pegfilgrastim (Neulasta)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
One injection per chemotherapy cycle instead of a daily white cell injection
Protamine Sulfate
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Switching off heparin when someone has had too much of it, or when the operation using it has finished
Recombinant Factor VIIa (NovoSeven RT / Sevenfact)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Stopping bleeding in people with haemophilia whose bodies have learned to destroy the replacement clotting factor they used to be given
Romiplostim (Nplate)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
A weekly injection that tells the bone marrow to make more platelets — and, separately, the drug stockpiled to keep people alive after a radiation accident
Four-Factor Prothrombin Complex Concentrate (Kcentra / Beriplex / Confidex; Octaplex and Balfaxar are separate products)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Putting back the clotting proteins that warfarin has switched off, in someone who is bleeding badly or needs surgery within hours
Abatacept (Orencia)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Moderately to severely active rheumatoid arthritis
Anakinra (Kineret)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Neonatal-Onset Multisystem Inflammatory Disease
Aflibercept-Abzv (Enzeevu)
Protein medicineApproved in the United States (FDA)Expanded recordBelatacept (Nulojix)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Prophylaxis of organ rejection
Insulin Human (Humulin R / Novolin 70/30 / Afrezza / Myxredlin / Novolin N / Humulin R U-500)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Glycemic control
Adalimumab-Ryvk (Simlandi)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA): Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. ( 1.1 ) Juvenile Idiopathic Arthritis (JIA): Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
Certolizumab pegol (Cimzia)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Moderately to severely active rheumatoid arthritis
Insulin Aspart-Szjj (Merilog)
Protein medicineApproved in the United States (FDA)Expanded recordInsulin Lispro-Aabc (Lyumjev)
Protein medicineApproved in the United States (FDA)Expanded recordPegfilgrastim-Pbbk (Fylnetra)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Adaz (Hyrimoz)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Adbm (Cyltezo)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Adalimumab-adbm is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Adalimumab-Atto (Amjevita)
Protein medicineApproved in the United States (FDA)Expanded recordAflibercept-Mrbb (Ahzantive)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
These highlights do not include all the information needed to use AHZANTIVE safely and effectively. See full prescribing information for AHZANTIVE. Initial U.S. Approval: 2024 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) AHZANTIVE is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD)…
Agalsidase beta (Fabrazyme)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Adult and pediatric patients 2 years of age and older with confirmed Fabry disease
Denosumab-Kyqq (Aukelso / Bosaya)
Protein medicineApproved in the United States (FDA)Expanded recordGemtuzumab Ozogamicin (Mylotarg)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Newly-diagnosed CD33-positive acute myeloid leukemia
Metreleptin (Myalept)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The complications of leptin deficiency
Pegvisomant (Somavert)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Acromegaly
Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo)
Protein medicineApproved in the United States (FDA)Expanded recordTaliglucerase alfa (Elelyso)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Patients 4 years of age and older with a confirmed diagnosis of Type 1 Gaucher disease
Adalimumab-Aaty (Yuflyma)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
YUFLYMA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Adalimumab-Afzb (Abrilada)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
ABRILADA is a tumor necrosis factor (TNF) blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Adalimumab-Aqvh (Yusimry)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Bwwd (Hadlima)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Fkjp (Hulio)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Adalimumab-fkjp is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. J uvenile Idiopathic Arthritis (JIA) ( 1.2 ) : reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
Calaspargase Pegol-Mknl (Asparlas)
Protein medicineApproved in the United States (FDA)Expanded recordCerliponase alfa (Brineura)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The loss of ambulation
Collagen, Soluble, Fish Skin (Massage Cream For Stretch Marks / Aoao Retinol Anti-Aging Box Set / A0a0 Rice Ceramide Anti Wrinkle Age Essence Box Set / Aoa0 Snail Ginseng Cream)
Protein medicineApproved in the United States (FDA)Expanded recordCrovalimab-Akkz (Piasky)
Protein medicineApproved in the United States (FDA)Expanded recordDarbepoetin alfa (Aranesp)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Anemia due
Denileukin Diftitox-Cxdl (Lymphir)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Adet (Ponlimsi)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Bnht (Conexxence / Bomyntra)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Dssb (Ospomyv / Xbryk)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Nxxp (Bilprevda / Bildyos)
Protein medicineApproved in the United States (FDA)Expanded recordFaricimab-Svoa (Vabysmo)
Protein medicineApproved in the United States (FDA)Expanded recordLecanemab-Irmb (Leqembi / Lecanemab / Leqembi Iqlik)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Alzheimer’s disease
Parathyroid Hormone (Natpara)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Temporarily relieves discomfort caused by kidney issues, including occasional mild to severe aches, urinary obstruction, intense nausea with or without vomiting, and inability to completely empty the bladder.* *CLAIMS BASED ON TRADITIONAL HOMEOPATHIC PRACTICE, NOT ACCEPTED MEDICAL EVIDENCE, NOT FDA EVALUATED. This product is not intended to diagnose, treat, cure, or prevent any disease.
Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Aacf (Idacio)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
IDACIO is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
Aflibercept-Ayyh (Pavblu)
Protein medicineApproved in the United States (FDA)Expanded record